Onconetix Inc ONCO Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$6.95 up $1.46, 26.59% at close Nov 6
Last close · Previous close $5.49
ONCO split 1-for-10 on ; earlier prices are adjusted for it.
- Market cap
- $7.97MAt the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$6.95up $1.46, 26.59%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$5.49Nov 5
- Volume699.58KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume347.25KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $3.42 to $1,610.00; now $6.95
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ONCO beat the S&P 500 in 1 of 5 periods.
| Period | ONCO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ONCO: up 5.1% S&P 500: down 5.6% | ONCO beat the S&P 500 by 10.7 percentage points Beat |
| 3M | ONCO: down 23.1% S&P 500: down 4.1% | ONCO trailed the S&P 500 by 19.0 percentage points Trailed |
| YTD | ONCO: down 99.1% S&P 500: up 8.7% | ONCO trailed the S&P 500 by 107.8 percentage points Trailed |
| 1Y | ONCO: down 99.5% S&P 500: up 10.9% | ONCO trailed the S&P 500 by 110.4 percentage points Trailed |
| Long term | ||
| 3Y | ONCO: down 100.0% S&P 500: up 75.0% −97.8% vs +20.5% a year | ONCO trailed the S&P 500 by 175.0 percentage points Trailed |
$10,000 invested in ONCO a year ago (Nov 6, 2025) would be worth about $52 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $11,088.
ONCO beat the S&P 500 in 1 of 5 periods.
| Period | ONCO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ONCO: up 5.1% S&P 500: down 5.6% | ONCO beat the S&P 500 by 10.7 percentage points Beat |
| 3M | ONCO: down 23.1% S&P 500: down 4.3% | ONCO trailed the S&P 500 by 18.8 percentage points Trailed |
| YTD | ONCO: down 99.1% S&P 500: up 7.8% | ONCO trailed the S&P 500 by 106.9 percentage points Trailed |
| 1Y | ONCO: down 99.5% S&P 500: up 9.7% | ONCO trailed the S&P 500 by 109.2 percentage points Trailed |
| Long term | ||
| 3Y | ONCO: down 100.0% S&P 500: up 68.8% −97.8% vs +19.1% a year | ONCO trailed the S&P 500 by 168.8 percentage points Trailed |
$10,000 invested in ONCO a year ago (Nov 6, 2025) would be worth about $52 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,969.
All-time high
$115,429,999.83
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Feb 18, 2022.
Stock splits
5
Latest: 1-for-10 on . Share counts adjust after each split.
All 5 splits
- 1-for-10
- 1-for-10
- 1-for-5
- 1-for-85
- 1-for-40
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- 12.3×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −129.37%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $2.21MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own ONCO DCF in Excel. Value Onconetix with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $645.82Kdown 51.3%
- Net income
- −$10.20M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $406.86K | −$3.83M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $711.98K | −$29.44M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $101.63K | −$8.55M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $106.49K | −$2.37M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $303.65K | −$8.78M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $303.60K | $5.67M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $21.46K | −$4.21M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $17.12K | −$2.87M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$3.42M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$13.42M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $58.47K | −$37.41M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $2.52M | −$58.69M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $815.37K | −$14.03M | Paused See the note under the price. |
Margins
- Gross 80.4%
- Operating −2,525.0%
- Net −1,578.8%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$10.31MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$10.31MLast 12 months
- Capital spending$0.00Last 12 months
- −1,596.1%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $4.65MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $5.94MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$187.13KAs of Jun 30, 2026
- Net cash$5.76MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 2.21As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.01As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✗Operating cash flow exceeded net income: not passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −92.0%Last 12 months
Over the last 12 months, Onconetix lost money: its net loss was 92.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −53.8%Last 12 months
Over the last 12 months, Onconetix’s net loss was 53.8% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Onconetix Inc
Onconetix is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology. Through our recent acquisition of Proteomedix, we own Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union (“EU”) under the In Vitro Diagnostic Regulation (“IVDR”). We also own ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia (“BPH”), a disorder of the prostate.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Ohio, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ONCO news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ONCO stock FAQ
What is ONCO stock’s price today?
Onconetix (ONCO) traded at $6.95 at the close on , up $1.46 (26.59%) from the previous close of $5.49. Over the past 52 weeks it has traded between $3.42 and $1,610.00.
What is Onconetix’s market cap?
Onconetix’s market capitalization is about $8.0 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $6.95 (how market cap works).
How much revenue does Onconetix make?
Onconetix reported $645.8 thousand of revenue over the four quarters to , down 51.3% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $17.1 thousand, down 83.9% from a year earlier.
Is Onconetix profitable?
Not over the four quarters to . Onconetix reported a net loss of $10.2 million across those four quarters on $645.8 thousand of revenue.
Does ONCO pay a dividend?
Onconetix hasn’t paid a dividend in the last twelve months.
What is ONCO’s 52-week high and low?
Over the past 52 weeks ONCO has traded as low as $3.42 and as high as $1,610.00. At $6.95 at the close on , it is 99.6% below that high and 103.0% above the low.
What is ONCO’s all-time high?
ONCO’s highest closing price was $115,429,999.83 on , adjusted for stock splits. At $6.95 at the close on , it is 100.0% below that record.
Has ONCO stock ever split?
Yes, five times: 1-for-40 on ; 1-for-85 on ; 1-for-5 on ; 1-for-10 on ; 1-for-10 on .
How has ONCO stock performed?
Including dividends and measured to the close on , ONCO has returned −99.1% so far this year and −99.5% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.7% and +10.9%. Past performance doesn’t predict future returns.
What sector and industry is Onconetix in?
Onconetix is in the Healthcare sector and the Biotechnology industry, and is headquartered in Ohio, USA.
What exchange does ONCO trade on?
Onconetix trades on the Nasdaq under the ticker symbol ONCO. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.